Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 17/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | METAP2 | P50579 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30156054 | 1.00 | TGFBR1 (0.42) | TGFBR1MAPK14MEN1ALDH1A1MAPT | |
| SCHEMBL25822564 | 0.88 | TGFBR1 (0.44) | TGFBR1MAPK14METAP2MTOR | |
| SCHEMBL30156368 | 0.87 | TGFBR1 (0.44) | TGFBR1MAPK14MTOR | |
| SCHEMBL25084658 | 0.87 | TGFBR1 (0.44) | TGFBR1MAPK14MTOR | |
| SCHEMBL29796486 | 0.86 | TGFBR1 (0.42) | TGFBR1MAPK14METAP2MTOR | |
| SCHEMBL23390013 | 0.86 | TGFBR1 (0.42) | TGFBR1MAPK14METAP2MTOR | |
| SCHEMBL25084697 | 0.86 | TGFBR1 (0.42) | TGFBR1MAPK14METAP2MTOR | |
| SCHEMBL30156263 | 0.86 | TGFBR1 (0.42) | TGFBR1MAPK14METAP2MTOR | |
| SCHEMBL23418587 | 0.86 | TGFBR1 (0.42) | TGFBR1MAPK14METAP2MTOR | |
| SCHEMBL25084690 | 0.86 | TGFBR1 (0.40) | TGFBR1MAPK14METAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11590116-B2 | Substituted pyridines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11590116-B2 | Substituted pyridines and methods of use | ALK, ACVR1, ACVR2A | TGFBR1 211/4885MAPK14 1504/4885MEN1 3345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.